The health professionals.
It's all based on the science. This is what the published peer-reviewed clinical trials and research showed. If you have trouble with going into lows while you're asleep, then your physician should seriously look at using insulin glargine as a way to keep you stable.
When the recommendation came out of the CDR not to list, we were very surprised. We wrote letters saying, “This is what our review of the science shows.” We illustrated what each country did. We said, “It's listed in all these countries. How did you reach a different conclusion?”
Well, we chatted with them, and we could not agree. They couldn't give us the information. One of the challenges has always been that they will say it's not cost-effective. We say, “Well, okay, share with us the economic information that you have to make that decision,” and they'll say, “No, we can't, because industry has made us sign a confidentiality agreement. We can't release that information to you.” We then go to industry, and we say, “Will you share the economic analysis with us?”, and industry says, “No, CDR won't let us share it with you.”
We can't find the economic rationale that they used, so we can only surmise that they're using the same studies as we used to come up with a cost-effectiveness number that says it's not cost-effective. And that seems to be their main recommendation—it's not cost-effective, and it's not useful.